Crown Bioscience International
| Company type | Public |
|---|---|
| Industry | Contract research organizations Pharmaceutical Biotechnology Biopharmaceutical |
| Headquarters | San Diego, California, United States |
Key people | www.crownbio.com/about-us/leadership-team |
| Services | Preclinical and translational drug research and development platforms for in vivo, in vitro, ex vivo, patient-derived xenograft (PDX), cell line-derived xenograft (CDX), organoids and 3D models, biomarker, bioanalysis, bioinformatics, and oncology databases |
| Website | www.crownbio.com/ |
Crown Bioscience is a global contract research organization (CRO) that provides preclinical and translational research services to accelerate drug discovery and development. Founded in 2006, Crown Bioscience is headquartered in San Diego, California. It also has 12 other sites throughout the United States, Europe, and APAC. The company offers platforms and services to advance oncology and immuno-oncology.
The company was acquired by JSR Corporation in January 2018.[1] It is part of JSR Life Sciences which was formed in 2002.
Crown Bioscience is known for capabilities in in vivo, in vitro, and ex vivo preclinical models. It works with companies in the pharmaceutical and biotechnology industries to assess and quantify the efficacy and pharmacological profile of drug candidates before they move into the clinic.
Products[edit]
Crown Bioscience is a company that offers a range of preclinical and translational drug research and development platforms and services. These include in vivo, in vitro, ex vivo patient derived xenograft (PDX), cell line derived xenograft (CDX), organoids and 3D models, as well as oncology databases, biomarker, bioanalysis and bioinformatics services. These models and platforms are intended for contract research in pharmaceutical and biotechnology drug discovery development. Crown Bioscience's in vivo and in vitro models provide predictive data on drug efficacy and safety. The PDX and CDX models offered by Crown Bioscience reflect the complexity of human tumors.
History[edit]
Over the years, the company has achieved many milestones that have contributed to its growth. The following is a history timeline of Crown Bioscience:
2006: Crown Bioscience Inc. was founded, and an R&D center was established in Beijing, China.
2007: An oncology platform was established.
2008: A new R&D center was founded in Taicang, China.
2009: Crown Bioscience US R&D site was founded.
2013: The company acquired PRECOS Ltd. (now Crown Bioscience UK Ltd.), and a bioluminescence imaging platform was established.
2014: Crown Bioscience Taiwan was founded.
2015: The western PDX models were expanded, and the company acquired Molecular Response (now Crown Bioscience San Diego, US).
2016: Crown Bioscience had its initial public offering on the Taiwan Stock Exchange.
2017: An inflammation platform was established, and the UK and US oncology facilities were expanded.
2018: The bioinformatics facilities were expanded in Suzhou, China, and the company was acquired by JSR Corporation.
2019: The organoid platform was established, and Crown Bioscience entered into a strategic partnership with Hubrecht Organoid Technology (HUB).
2020: The China oncology facilities in Zhongshan were expanded, and the Crown Bioscience Netherlands organoid center was founded.
2021: The company acquired Ocello B.V., and its in vitro capability was expanded.
2022: Crown Bioscience and MBL joint venture was established in Japan.
2023: Crown Bioscience Singapore was founded and IndivuServ business unit of Indivumed GmbH acquired.[2]
Acquisitions[edit]
In July 2013, Crown Bioscience acquired PRECOS Ltd., now known as Crown Bioscience UK Ltd.[3]
In 2015, Crown Bioscience acquired Molecular Response, now Crown Bioscience San Diego, US, to expand its PDX and tumor biobank models and services portfolio.[4]
The acquisition of Crown Bioscience by JSR Corporation in 2018 allowed the company to extend its portfolio to include contract research and development capabilities.[5]
In July 2021, the company announced it would acquire Ocello B.V., located in the Netherlands, to expand its portfolio of in vitro and high-content imaging services.[6]
In March 2023, the business announced it would acquire the IndivuServ business unit of Indivumed GmbH. Based in Hamburg, Germany, a Share Purchase Agreement (SPA) between both parties was executed on December 29, 2022, and subject to customary closing adjustments, the transaction is expected to close in April 2023.[7]
References[edit]
- ^ Fassbender, Melissa (4 January 2018). "JSR: CrownBio purchase to support 'major opportunity' in preclinical space". Outsourcing-Pharma. Retrieved 29 January 2018.
- ^ "Crown Bioscience to Acquire Indivumed's Service Business and Supporting Biobank". Crown Bioscience. January 25, 2023.
- ^ "Crown Bioscience Acquires PRECOS". Technology Networks. August 5, 2013.
- ^ "Crown Bioscience Acquires Molecular Response's Patient Derived Xenograft (PDX) Business". Crown Bioscience. February 12, 2015.
- ^ "JSR Announces Acquisition of Crown Biosciences International". JSR Life Sciences. December 20, 2017.
- ^ "Crown Bioscience Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings". Crown Bioscience. May 5, 2021.
- ^ "Crown Bioscience to Acquire Indivumed's Service Business and Supporting Biobank". Crown Bioscience. January 25, 2023.